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Recurrent mutations in genes involved in nuclear factor-jB signalling in nodal marginal
zone lymphoma—diagnostic and therapeutic implications
Aims: To investigate the spectrum of mutations in
20 genes involved in B-cell receptor and/or Toll-like
receptor signalling resulting in activation of nuclear
factor-jB (NF-jB) in 20 nodal marginal zone lym-
phomas (NMZLs), 20 follicular lymphomas (FLs), and
11 cases of B-cell lymphoma, unclassifiable (BCL-u).
Methods and results: Nodal marginal zone lym-
phomas were diagnosed according to strict criteria,
including the expression of at least one putative mar-
ginal zone marker (MNDA and/or IRTA1). Cases that
showed features of NMZL but did not fulfil all criteria
were included as BCL-u. All FLs were required to
have a BCL2 rearrangement. Mutations were found
in: nine NMZLs, with recurrent mutations in
TNFAIP3 and CD79B; 12 FLs, with recurrent
mutations in TNFRSF14, TNFAIP3, and CARD11;
and five cases of BCL-u, with recurrent mutations in
TNFRSF14. TNFRSF14 mutations were present in FL
and BCL-u, but not in any of the NMZLs. In the
BCL-u group, TNFRSF14 mutations clustered with a
FL immunophenotype.
Conclusions: These results suggest that TNFRSF14
mutations point towards a diagnosis of FL, and can
be used in the sometimes difficult distinction
between NMZL and FL, but to apply this in diagnos-
tics would require confirmation in an independent
cohort. In addition, the presence or absence of speci-
fic mutations in pathways converging on NF-jB
could be important for decisions regarding targeted
treatment.
Keywords: diagnosis, follicular lymphoma, nodal marginal zone lymphoma, non-Hodgkin lymphoma, nuclear
factor-jB, TNFAIP3, TNFRSF14
Introduction
Nodal marginal zone lymphoma (NMZL) is a rare
type of low-grade B-cell non-Hodgkin lymphoma that
is currently defined as a primary nodal B-cell neo-
plasm resembling lymph node involvement by splenic
or extranodal marginal zone lymphoma, but without
evidence of splenic or extranodal disease.1 A diagno-
sis of NMZL is complicated by the fact that little is
known about its pathogenesis, which is reflected by a
lack of routinely used positive markers for a diagnosis
of NMZL. Therefore, NMZL is often a diagnosis of
exclusion, resulting in a heterogeneous disease
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category. In particular, the distinction between NMZL
and follicular lymphoma (FL) can be problematic.2
Several novel immunohistochemical markers for
NMZL have been reported, including IRTA1 and
MNDA.3–5 Addition of these markers to the usual
diagnostic procedures could potentially result in a
more reliable diagnosis of NMZL. Along these lines,
we have recently described an immunohistochemical
algorithm, including both established and novel
markers, to help differentiate between NMZL and FL.6
The nuclear factor-jB (NF-jB) pathway has an
important role in B-cell functioning, with signals from
different receptors, including B-cell receptor (BCR),
tumour necrosis factor (TNF) receptor (TNFR), inter-
leukin-1 receptor (IL1R), and Toll-like receptor (TLR),
converging on NF-jB. In BCR signalling, binding of
BCR by antigen causes phosphorylation of CD79A
and CD79B, which initiates a signalling cascade
involving multiple proteins, including Bruton’s tyro-
sine kinase (BTK) and protein kinase Cb. This results
in phosphorylation of CARD11,7,8 which then associ-
ates with bcl-10, which in turn binds MALT1.9–14
The CARD11–bcl-10–MALT1 complex then interacts
with TRAF2 and TRAF6, which induces inhibitor of
IjB kinase (IKK) complex activation.9 The IKK com-
plex phosphorylates NF-jB inhibitors, causing them
to be degraded by the proteasome, thereby exposing
nuclear localization signals on NF-jB dimers, result-
ing in their sustained nuclear localization and bind-
ing of DNA for transcriptional regulation. IL1R and
TLRs signal via receptor-bound MYD88, IRAK, and
TRAF6, also resulting in IKK complex activation.
Stimulation of TNFR causes IKK complex activation
via yet another pathway, involving the proteins
RIP1, TAK1, and TAB2. In addition to canonical NF-
jB signalling, a non-canonical pathway exists, in
which signalling from lymphotoxin B receptor, B-cell
activating factor receptor and CD40 activates NF-jB.
Mutations in genes involved in NF-jB signalling have
been reported in many subtypes of lymphoma,15 includ-
ing extranodal and splenic marginal zone lym-
phomas.15–17 As NMZL resembles its extranodal
counterparts, the NF-jB pathway could also be activated
in NMZL. Indeed, enrichment of expression of genes
involved in NF-jB signalling has been shown in NMZL.18
The gene encoding the inhibitor of NF-jB signalling
TNFAIP3, has been suggested to be a tumour suppressor
gene in extranodal marginal zone lymphomas,19–21 and
TNFAIP3 mutations have also been detected in a small
series of NMZLs (in three of nine cases).22
In the study presented here, we investigated 20
strictly defined NMZLs for the presence of mutations
in genes involved in BCR and/or TLR signalling
resulting in activation of NF-jB. We compared these
with 20 FLs and a group of 11 cases of B-cell lym-
phoma, unclassifiable (BCL-u). The latter group had
been diagnosed as possible NMZL in routine diagnos-
tics, but did not fulfil the strict criteria for NMZL used
in this study.
Knowledge of the presence of NF-jB-activating
mutations in NMZL is of potential benefit for diagno-
sis and prognostication. In addition, it carries great
promise for targeted treatment. Given the importance
of BCR–TLR–NF-jB signalling in many subtypes of
lymphoma, an increasing array of drugs are being
developed that target specific components of these
pathways. Knowledge of the spectrum of mutations
occurring in a specific lymphoma has the potential to
enable prediction of which drugs this lymphoma will
respond to.
Materials and methods
P A T I E N T S E L E C T I O N
Thirty-one cases of possible NMZL and 20 cases of FL
diagnosed between 2003 and 2014 were collected
from the archive of the Department of Pathology at
the Radboud University Medical Centre (Nijmegen,
the Netherlands).
This study was reviewed and approved by the local
ethical committee (reference number 2011/270).
Clinically, for a diagnosis of NMZL, patients were
required to present with nodal disease without extra-
nodal involvement other than the bone marrow.
Also, a clinical presentation with Waldenstr€om
macroglobulinaemia was an exclusion criterion. The
morphological criteria for NMZL were used as previ-
ously reported.6
For immunohistochemistry, all lymphomas were
stained with an extensive panel of germinal centre
markers (CD10, bcl-6, LMO2, and HGAL) and puta-
tive marginal zone markers (MNDA and IRTA1). As
recently described, we used these markers to classify
the tumour, according to an algorithm, into one of
three categories: (i) NMZL, for lymphomas expressing
fewer than two germinal centre markers and either
MNDA or IRTA1; (ii) FL, for lymphomas expressing
all four germinal centre markers or expressing two or
three germinal centre markers in the absence of
MNDA and IRTA1; and (iii) low-grade BCL-u, for
lymphomas not fitting into one of the two categories
described above.6 To be included as NMZL in this
study, an algorithm result of ‘NMZL’ was required.
Finally, the presence of a BCL2 translocation was
excluded in all NMZLs by the use of fluorescence in-
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situ hybridization (FISH) with a split-probe approach.
FISH experiments were performed as described previ-
ously, by use of a similar protocol with split probes
against BCL2 (Dako Y5407; Dako, Glostrup, Den-
mark) or BCL6 (Dako Y5408; Dako).6
From the 31 cases of possible NMZL that were
selected from the archive, 20 could be included as
NMZL in the study after application of the strict criteria
indicated above. The other 11 cases fulfilled the clini-
cal, morphological and cytogenetic criteria for NMZL,
but were not classified as ‘NMZL’ by the immunohisto-
chemical algorithm. These cases were included in the
study as BCL-u. The clinical features of patients with
NMZL, FL and BCL-u are shown in Table 1.
N E X T - G E N E R A T I O N S E Q U E N C I N G
A custom Ion AmpliSeq panel (Life Technologies,
Bleiswijk, the Netherlands) was used, consisting of
410 primer combinations, covering the entire coding
sequence or specific regions of interest of 20 genes
involved in TLR–BCR–NF-jB signalling (Table S1),
achieving a theoretical coverage of 94.4% of the
defined targets (Table S2).
Amplicon libraries were generated in two pools
with 20 ng of DNA input per pool, according to the
manufacturer’s instructions (Life Technologies).
Sequencing was performed on an Ion Personal Gen-
ome Machine 200 (Life Technologies), with one Ion
318 chip per four DNA samples. Figure S1 shows the
percentage of amplicons reaching different depths of
coverage.
Sequences were analysed with the SEQNEXT software
package (JSI Medical Systems, Kippenheim, Ger-
many). Variants were called if the absolute number
of variant reads was ≥25, if the ratio of forward ver-
sus reverse read directions did not exceed 30%/70%,
and if the variant constituted at least 10% of the
Table 1. Patient characteristics
NMZL (n = 20) BCL-u (n = 11) FL (n = 20)
Male/female (n) 12:8 6:5 12:8
Median age (years) 64 56 59
Tumour localization, n (%)
Nodal 20 (100) 11 (100) 19 (95)
Extranodal 0 (0) 0 (0) 1 (5) (parotid gland)
Ann Arbor stage, n (%)
I 6 (30) 2 (18) 1 (5)
II 2 (10) 3 (27) 3 (15)
III 3 (15) 2 (18) 3 (15)
IV 6 (30) 2 (18) 11 (55)
Unknown 3 (15) 2 (18) 2 (10)
B-symptoms, n (%) 1/14 (7) 1/10 (10) 2/18 (11)
Bone marrow involvement, n (%) 7/15 (47) 1/10 (10) 10/16 (63)
Concurrent diffuse large B-cell lymphoma at diagnosis, n (%) 1 (5) 1 (9) 0 (0)
Transformation during follow-up, n (%) 2/16 (13) 0/10 (0) 7/19 (37)
Grade, n (%)
1–2 NA NA 14 (70)
3A NA NA 5 (25)
3B NA NA 1 (5)
BCL-u, B-cell lymphoma, unclassifiable; FL, follicular lymphoma; NA, not applicable; NMZL, nodal marginal zone lymphoma.
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reads. Intronic mutations, mutations in untranslated
regions and silent mutations were filtered out by
adaptation of the software settings. Variants were
called by the software, but variants that were also
present in reactive lymph nodes were considered to
be single-nucleotide polymorphisms (SNPs) or arte-
facts, and were excluded. For missense mutations,
in-silico pathogenicity predictions were performed
with POLYPHEN 2.0 (http://genetics.bwh.harvard.edu/
pph2/), ALIGN-GVGD, and SIFT, by use of the ALAMUT soft-
ware package (Version 2.1; Interactive Biosoftware,
Rouen, France). Variants that were predicted not to
be pathogenic by all prediction programs were con-
sidered to be benign, and excluded. Mutations were
confirmed by conventional Sanger chain-terminating
sequencing in duplicate.
S T A T I S T I C A L A N A L Y S I S
Data were analysed with IBM SPSS STATISTICS version 20
(IBM, Armonk, NY, USA). Pearson’s chi-square test
was used for comparison of categorical variables. Sur-
vival analysis was performed by the use of Kaplan–
Meier statistics with log-rank tests. Overall survival
was defined as the time from date of diagnosis until
the time of last follow-up or death. Event-free survival
was defined as the time from date of diagnosis until
the time of last follow-up or an adverse event (disease
progression, relapse, second tumour, or death from
any cause). Two-tailed P-values of ≤0.05 were con-
sidered to be statistically significant.
Results
R E C U R R E N T M U T A T I O N S I N G E N E S I N V O L V E D I N
B C R – T L R – N F - j B S I G N A L L I N G
In NMZL, nine of 20 cases (45%) showed mutations
in one or more of the genes tested, and in FL 12 of
20 cases (60%) showed mutations, but the genes
involved were different.
In NMZL, mutations were most frequently observed
in TNFAIP3 (six cases, 30%) and CD79B (two cases,
10%) (Figure 1A; Table 2). In single cases, mutations
were observed in CARD11, MYD88, and TNIP2. In
FL, mutations in TNFRSF14 were most frequent (five
cases, 25%), followed by TNFAIP3 (three cases, 15%),
and CARD11 (three cases, 15%) (Figure 1B; Table 3).
Mutations in CD79B, MAP3K3 and MAP3K7 were
observed in single cases.
In the BCL-u group, mutations in TNFRSF14 were
most frequent, being present in four of 11 cases
(36%) (Figure 1C; Table 4). Single mutations were
observed in TNFAIP3, TRAF3 and TRAF7 in this
group. In all but one case, mutations in TNFAIP3
and TNFRSF14 were mutually exclusive.
Mutations in TNFAIP3 or TNFRSF14 did not
significantly correlate with disease stage, the presence
of B-symptoms, overall survival, or progression-free
survival (data not shown).
T N F R S F 1 4 M U T A T I O N S C L U S T E R W I T H D I A G N O S I S
With the strict criteria for NMZL used in this study,
TNFRSF14 mutations were not observed in any of
the NMZLs. In contrast, TNFRSF14 was the most fre-
quently mutated gene in both the FL group and the
BCL-u group, being present in 25% and 36%,
respectively.
C L I N I C O P A T H O L O G I C A L D I F F E R E N C E S B E T W E E N
N M Z L A N D B C L - U
To investigate additional differences between the
NMZL and BCL-u groups, we compared the clinico-
pathological features of these two groups. NMZLs
showed a trend towards more frequent bone marrow
involvement, with bone marrow involvement in eight
of 15 (53%) patients with NMZL, but in only one of
10 (10%) patients with BCL-u (P = 0.054).
Rearrangements involving BCL6 were observed in
four of 11 (36%) cases of BCL-u, but in only one of
19 (5%) NMZLs (P = 0.028; Figure 1). No clear dif-
ferences were observed in disease stage, the presence
of B-symptoms, or rate of transformation (Table 1).
Overall and event-free survival were also similar
between the two groups (Figure 2).
Discussion
NF-jB transcription factors have important roles in
multiple cellular processes, including cell survival,
maturation, response to stress, and immune
responses. Not surprisingly, NF-jB signalling has a
role in oncogenesis; many solid tumours and haema-
tological malignancies show activated NF-jB,23 mak-
ing it an interesting treatment target. Indeed,
therapeutic agents that target BCR–TLR–NF-jB sig-
nalling (including bortezomib, carfilzomib, lenalido-
mide, ibrutinib, and idelalisib) are increasingly
becoming available. To select patients who will bene-
fit from targeted treatment, it will be important to
have information on mutations in these pathways.
This has been most extensively studied in diffuse
large B-cell lymphoma (DLBCL), in which ibrutinib
© 2016 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 70, 174–184.
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was shown to be more effective in patients with the
activated B-cell-like subtype of DLBCL than in those
with the germinal centre B-cell-like subtype.24 This
can be explained by the frequent presence of muta-
tions that activate BCR signalling in activated B-cell-
like DLBCL, including mutations in CD79A/CD79B,
CARD11, and MYD88. Interestingly, MYD88 muta-
tions in the absence of CD79A/CD79B mutations pre-
dicted resistance to ibrutinib, which can be explained
by the fact that MYD88 activates NF-jB indepen-
dently of BTK.24 However, tumours with MYD88
mutations in combination with CD79A/CD79B muta-
tions did respond to ibrutinib, which cannot be read-
ily explained by known signalling pathways.
In this study, we focused on mutations in genes
involved in NF-jB signalling in NMZL, the rationale
being that an NF-jB signature has been shown in
NMZL,18 and that other marginal zone lymphomas
A Nodal marginal zone lymphoma
B Follicular lymphoma C B-cell lymphoma, unclassifiable
BIRC3
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CD79A
CD79B
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IKBKB
MAP3K3
MAP3K7
MAP3K14
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TNFAIP3
TNFRSF11A
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TRAF3
TRAF5
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BCL6 rearr.
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F F F F F U U UF F F F F F F F F F F F F F F F U U U U U U FAlgorithm Algorithm
Figure 1. Mutations detected in nodal marginal zone lymphoma (NMZL) (A), follicular lymphoma (FL) (B), and B-cell lymphoma, unclassifi-
able (BCL-u) (C). For a diagnosis of NMZL, both the morphological features and the immunohistochemical algorithm result supported this
diagnosis. If the morphological features were consistent with NMZL, but the immunohistochemical algorithm did not support this diagnosis,
the case was classified as BCL-u. All cases included as FL carried a BCL2 rearrangement. Mutations are indicated in red. The result from the
immunohistochemical algorithm is indicated in the row labelled ‘algorithm’, with a result consistent with FL as ‘F’ and a result of BCL-u as
‘U’. For all cases included as NMZL in this figure, the immunohistochemical algorithm showed a result consistent with NMZL. The final rows
of (A) and (C) show the presence of a BCL6 rearrangement in red, which was studied with fluorescence in-situ hybridization.
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are also characterized by lesions in genes involved in
NF-jB signalling.15 Importantly, for a case to be
included as NMZL, it had to fulfil strict criteria,
including immunohistochemical expression of at least
one putative marginal zone marker (MNDA and/or
IRTA1). For comparison, we studied 20 cases of typi-
cal FL, all with a BCL2 rearrangement. Finally, we
included 11 unclassifiable cases that had been diag-
nosed as possible NMZL in routine diagnostics, but
could not fulfil the strict criteria used for NMZL in
this study.
Overall, we found fewer mutations in NMZLs than
in FLs, and the patterns were different. TNFAIP3
mutations were the most frequent abnormalities
detected in NMZLs. TNFAIP3 mutations have been
reported previously in lymphomas, including mar-
ginal zone lymphomas,16,21,22,25,26 FL,27 and
DLBCL.28 Under normal circumstances, TNFAIP3
Table 2. Mutations affecting nuclear factor-jB pathway genes in nodal marginal zone lymphoma
Gene Sample no. Nucleotide changea Exon
Allelic
frequency
(%) Pathogenicity descriptionb
TNFAIP3 1002 c.2062G>T p.(Glu688*) 8 10 Known tumour suppressor gene, truncating
(nonsense) or frameshift mutations ? pathogenic
1007 c.346C>T p.(Gln116*) 3 33 As above
1013 c.301_302delinsATGAGGACA
p.(Gly101Metfs*41)
3 23 As above
c.338_341del p.(Trp113Serfs*9) 7 15 As above
1018 c.426G>A p.(Trp142*) 3 21 As above
c.1035C>G p.(Tyr345*) 7 27 As above
1031 c.296_315del p.(Gly99Alafs*34) 3 14 As above
1053 c.751dup p.(Tyr252Leufs*2) 5 10 As above
c.826_827dup p.(Asn277Leufs*11) 6 18 As above
CARD11 1031 c.1078A>G p.(Met360Val) 8 33 Known oncogene, missense mutation in coiled coil
domain ? probably pathogenic
CD79B 1032 c.586_588del p.(Tyr196del) 5 31 Known oncogene, deletion and missense mutation in
the ITAM domain, which is needed for signal
transduction ? probably pathogenic
1050 c.586T>G p.(Tyr196Asp) 5 46 As above
MYD88 1052 c.794T>C p.(Leu265Pro) 5 11 Oncogene/tumour suppressor gene not known, missense
mutation in hotspot, 3/3 prediction programs predict
deleterious mutation ? probably pathogenic
ALIGN-GVGD: class C65
SIFT: deleterious (score 0.01)
POLYPHEN 2.0: probably damaging (score 1.000)
TNIP2 1052 c.787C>T p.(Arg263Trp) 4 49 Oncogene/tumour suppressor gene not known,
missense mutation in hotspot, 3/3 prediction programs
predict deleterious mutation ? probably pathogenic
ALIGN-GVGD: class C65
SIFT: deleterious (score 0)
POLYPHEN 2.0: probably damaging (score 1.000)
aNumbering according to: NM_001270508.1/ENST00000612899 (TNFAIP3); NM_003820.2/ENST00000355716 (TNFRSF14);
NM_0032415.5/ENST00000396964 (CARD11); NM_000626.2/ENST00000006750 (CD79B); NM_002468.4/ENST00000396334 (MYD88);
NM_024309.3/ENST00000315423 (TNIP2); NM_003300.3/ENST00000560371 (TRAF3); NM_032271.2/ENST00000326181 (TRAF7).
b
ALIGN-GVGD: Grantham Variation Grantham Deviation; risk classes are C0, C15, C25, C35, C45, C55, and C65, with higher classes indicating
a higher risk of a damaging mutation. SIFT: Sorts Intolerant From Tolerant; scores range from 0 to 1, with a score of ≤0.05 predicted to be
damaging. POLYPHEN 2.0: scores range from 0 to 1, with higher scores predicted to be more damaging.
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Table 3. Mutations affecting nuclear factor-jB pathway genes in follicular lymphoma
Gene Sample Mutationa Exon
Allelic
frequency
(%) Pathogenicity descriptionb
TNFAIP3 2024 c.477T>A p.(Tyr159*) 3 77 Known tumour suppressor gene, truncating
(nonsense) or frameshift
mutations ? pathogenic
2003 c.2090_2091del p.(Arg697Ilefs*54) 9 23 As above
2048 c.190_191delinsGA p.(Ile64Asp) 2 54 Missense mutation, 3/3 prediction programs predict
deleterious effect ? probably pathogenic
ALIGN-GVGD: class C45
SIFT: deleterious (score 0)
POLYPHEN 2.0: probably damaging (score 0.999)
c.101A>G p.(Asn34Ser) 2 56 Missense mutation, 0/3 prediction programs predict
deleterious mutation ? probably not pathogenic
ALIGN-GVGD: class C0
SIFT: tolerated (score 0.22)
POLYPHEN 2.0: benign (score 0.004)
TNFRSF14 2002 c.36G>A p.(Trp12*) 1 30 Known tumour suppressor gene, truncating (nonsense)
or frameshift mutations ? pathogenic
2009 c.423C>G p.(Tyr141*) 4 43 As above
2003 c.357_358del p.(Cys119Trpfs*114) 4 19 As above
c.71T>A p.(Val24Glu) 2 18 Missense mutation, 1/3 prediction programs predict
deleterious effect ? possibly pathogenic
ALIGN-GVGD: class C0
SIFT: tolerated (score 0.13)
POLYPHEN 2.0: probably damaging (score 0.999)
c.103T>C p.(Tyr35His) 2 18 Missense mutation, 0/3 prediction programs predict
deleterious effect ? probably not pathogenic
ALIGN-GVGD: class C0
SIFT: tolerated (score 0.54)
POLYPHEN 2.0: benign (score 0.369)
2012 c.552G>C p.(Lys184Asn) 6 47 Missense mutation, 1/3 prediction programs predict
deleterious effect ? possibly pathogenic
ALIGN-GVGD: class C0
SIFT: tolerated (score 0.34)
POLYPHEN 2.0: possibly damaging (score 0.588)
2013 c.334T>C p.(Ser112Pro) 4 24 Missense mutation, 1/3 prediction programs predict
deleterious effect ? possibly pathogenic
ALIGN-GVGD: class C0
SIFT: tolerated (score 0.1)
POLYPHEN 2.0: probably damaging (score 0.997)
CARD11 2010 c.644A>T p.(Lys215Met) 5 39 Known oncogene, missense mutation in coiled coil
domain ? probably pathogenic
2018 c.746A>C p.(Gln249Pro) 6 43 As above
2049 c.752T>C p.(Leu251Pro) 6 37 As above
CD79B 2013 c.617_618del p.(Thr206Ilefs*2) 6 28 Known oncogene, deletion and missense
mutation in the ITAM domain, which is
needed for signal transduction ? probably
pathogenic
© 2016 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 70, 174–184.
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functions as an inhibitor of NF-jB signalling at
multiple levels. Loss-of-function mutations cause
increased activation of NF-jB, resulting in reduced
apoptosis and cell proliferation.28,29 In FL, TNFAIP3
mutations have been reported in association with
transformation.27
TNFRSF14 was the most frequently mutated gene
in both FL and BCL-u. TNFRSF14 is a member of the
TNF receptor superfamily, and triggering of
TNFRSF14 has been suggested to render B cells more
susceptible to FAS-induced apoptosis.30,31 In line with
this, TNFRSF14 can act as a tumour suppressor in a
mechanism whereby mutations cause loss of function
and evasion of T-cell-mediated immune surveillance.
TNFRSF14 mutations have been reported in 18–46%
of FLs in previous studies and in 22% of DLBCLs.31–33
We found a lower percentage of mutated cases
(16%), which can be explained by the fact that, in
contrast to earlier studies, we did not investigate copy
number changes.
TNFRSF14 mutations were found frequently in FL,
but not in any of the NMZLs when strict criteria for
the latter diagnosis were used. These results suggest
that TNFRSF14 mutations do not constitute a feature
of NMZL, and that the presence of these mutations
can be of diagnostic help in ruling out a diagnosis of
NMZL. Furthermore, the fact that TNFRSF14 muta-
tions were frequent in the difficult category of BCL-u
is promising, because these lymphomas are difficult to
distinguish from FL. All but one case of BCL-u with a
TNFRSF14 mutation showed an FL immunopheno-
type, suggesting that TNFRSF14 mutations point
towards a diagnosis of FL. This is of potential diag-
nostic use in lymphomas in which differentiation
between NMZL and FL is difficult, but the numbers
are small, and these results should be confirmed in
an independent cohort before their use in diagnostics.
BCL6 rearrangements were found in only a single
case of NMZL, but in four of 11 cases of BCL-u.
Although the numbers are small, this suggests that
BCL6 rearrangements are rare in strictly defined
NMZL.
Interestingly, the association between the absence
of BCL2 translocations in FL and deletions of the
chromosomal region containing TNFRSF14 (1p36)
has been reported in patients who typically present
with low-stage inguinal disease with morphologically
diffuse FL.34 A direct comparison is difficult, however,
because, in the current study, we looked at mutations
rather than deletions of TNFRSF14, which were also
frequently detected in FLs with a BCL2 translocation.
In NMZL and BCL-u, single mutations were
detected in CARD11, MYD88, TNIP2, TRAF3, and
TRAF7. MYD88 is of particular interest, as the
L265P mutation in MYD88 has been described in the
large majority of lymphoplasmacytic lymphomas
(LPLs). The single NMZL in our series with a MYD88
mutation showed no plasmacytic differentiation. Also,
the patient did not present with a clinical syndrome
of hyperviscosity, fitting Waldenstr€om
Table 3. (Continued)
Gene Sample Mutationa Exon
Allelic
frequency
(%) Pathogenicity descriptionb
MAP3K3 2014 c.1616T>G p.(Phe539Cys) 16 12 Oncogene/tumour suppressor gene not known,
missense mutation, 2/3 prediction programs scores
predict deleterious mutation ? possibly pathogenic
ALIGN-GVGD: class C0
SIFT: deleterious (score 0)
POLYPHEN 2.0: probably damaging (score 1.000)
MAP3K7 2001 c.681A>T p.(Lys227Asn) 7 57 Oncogene/tumour suppressor gene not known,
missense mutation, 2/3 prediction programs scores
predict deleterious mutation ? possibly pathogenic
ALIGN-GVGD: class C0
SIFT: deleterious (score 0)
POLYPHEN 2.0: probably damaging (score 0.962)
aNumbering according to: NM_001270508.1/ENST00000612899 (TNFAIP3); NM_003820.2/ENST00000355716 (TNFRSF14);
NM_0032415.5/ENST00000396964 (CARD11); NM_000626.2/ENST00000006750 (CD79B); NM_203351.1/ENST00000361357
(MAP3K3); NM_145331.1/ENST00000369329 (MAP3K7).
b
ALIGN-GVGD: Grantham Variation Grantham Deviation; risk classes are C0, C15, C25, C35, C45, C55, and C65, with higher classes indicating
a higher risk of a damaging mutation. SIFT: Sorts Intolerant From Tolerant; scores range from 0 to 1, with a score of ≤0.05 predicted to be
damaging. POLYPHEN 2.0: scores ranging from 0 to 1, with higher scores predicted to be more damaging.
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macroglobulinaemia. We therefore believe that it is
justified to classify this lymphoma as an NMZL with a
MYD88 mutation. However, the distinction between
LPL and NMZL with a MYD88 mutation remains dif-
ficult, as was emphasized during the 2014 meeting of
the European Association for Haematopathology/
Society for Hematopathology meeting, in which
rare cases of NMZL with a MYD88 mutation were
recognized.35
In this study, we used a targeted approach, follow-
ing on from the hypothesis that reported mutations
in genes involved in NF-jB signalling could also have
a role in NMZL. This targeted approach allowed good
coverage of the genes tested, but limits our results to
this gene set only. It is likely that other mutations
are also important in NMZL pathogenesis, and,
accordingly, a recent study that combined whole
exome sequencing, deep sequencing of tumour-related
genes, a high-resolution SNP array and RNA
sequencing detected frequent abnormalities in JAK–
STAT, NOTCH, NF-jB and TLR signalling, including
frequent mutations in MLL2, PTPRD, and NOTCH2.36
In this study, among other genes, recurrent muta-
tions were also detected in TNFAIP3, TNFRSF14,
MYD88, BCL10, REL, CARD11, TRAF3, and BIRC3.
This highlights the fact that multiple pathways are
deregulated in NMZL, further complicating the predic-
tion of responses to different targeted treatments.
The number of different signalling pathways that
can be deregulated in lymphomas and the hetero-
geneity of mutations described already pose a chal-
lenge for therapy prediction, and this is further
complicated by other factors influencing responses to
specific targeted therapies, including the epigenome
and the tumour microenvironment. For the NF-jB
pathway, for example, activation can be caused by
mutations, paracrine signalling, and Epstein–Barr
virus infection, and it is possible that patients could
Table 4. Mutations affecting nuclear factor-jB pathway genes in B-cell lymphoma, unclassifiable
Gene Sample no. Nucleotide changea Exon
Allelic
frequency
(%) Pathogenicity descriptionb
TNFAIP3 1064 c.2107_2108del p.(Asp703Cysfs*48) 9 36 Known tumour suppressor gene, truncating (nonsense)
or frameshift mutations ? pathogenic
TNFRSF14 1028 c.283C>T p.(Gln95*) 3 20 Known tumour suppressor gene, truncating (nonsense)
or frameshift mutations ? pathogenic
1023 c.852A>G p.(*284Trpext*78) 8 65 As above
1058 c.477_487del p.(Asp159Glufs*71) 5 53 As above
1020 c.288C>G p.(Cys96Trp) 3 29 Missense mutation, 3/3 prediction programs predict
deleterious effect ? probably pathogenic
ALIGN-GVGD: class C65
SIFT: deleterious (score 0)
POLYPHEN 2.0: probably damaging (score 1.000)
TRAF3 1023 c.598G>T p.(Val200Leu) 6 36 Tumour suppressor gene, 1/3 prediction programs
predict possible deleterious effect ? possibly
pathogenic
ALIGN-GVGD: class C0
SIFT: tolerated (score 0.21)
POLYPHEN 2.0: possibly damaging (score 0.808)
TRAF7 1058 c.352C>A p.(Pro118Thr) 6 51 Oncogene/tumour suppressor gene not known,
1/3 prediction programs predict possible deleterious
effect ? possibly pathogenic
ALIGN-GVGD: class C0
SIFT: tolerated (score 0.08)
POLYPHEN 2.0: possibly damaging (score 0.651)
aNumbering according to: NM_001270508.1/ENST00000612899 (TNFAIP3); NM_003820.2/ENST00000355716 (TNFRSF14);
NM_003300.3/ENST00000560371 (TRAF3); NM_032271.2/ENST00000326181 (TRAF7).
b
ALIGN-GVGD: Grantham Variation Grantham Deviation; risk classes are C0, C15, C25, C35, C45, C55, and C65, with higher classes indicating
a higher risk of a damaging mutation. SIFT: Sorts Intolerant From Tolerant; scores range from 0 to 1, with a score of ≤0.05 predicted to be
damaging. POLYPHEN 2.0: scores range from 0 to 1, with higher scores predicted to be more damaging.
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benefit from therapy targeting the NF-jB pathway,
regardless of the exact mechanism. Therefore, ulti-
mately, it might be necessary to move towards func-
tional assays rather than mutation detection.
In conclusion, we detected frequent but heteroge-
neous mutations in genes related to BCR–TLR–NF-jB
signalling in both NMZL and FL. The strong correla-
tion between TNFRSF14 mutations and an FL
immunophenotype is of potential diagnostic use, but
confirmation in an independent cohort is warranted.
In addition, with the increase in the number of drugs
that target pathways that converge on NF-jB, thor-
ough knowledge of the mutational status of a lym-
phoma will be helpful to guide targeted treatment
decisions.
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